1. EGFR mutation status in a series of Turkish non-small cell lung cancer patients
- Author
-
Ilhan Oztop, Gizem Calibasi-Kocal, Tolga Sever, Arsalan Amirfallah, Yasemin Basbinar, Duygu Gürel, Hülya Ellidokuz, and Olcun Umit Unal
- Subjects
0301 basic medicine ,Microarray ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Exon ,0302 clinical medicine ,medicine ,Epidermal growth factor receptor ,General Pharmacology, Toxicology and Pharmaceutics ,Lung cancer ,Mutation ,biology ,business.industry ,General Neuroscience ,Cancer ,Articles ,General Medicine ,Cell cycle ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Carcinogenesis ,business - Abstract
Epidermal growth factor receptor (EGFR) mutations are potential markers driving carcinogenesis, and may alter the response to EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). The frequency of EGFR mutations in patients with NSCLC differs according to sex, smoking habits and regional-based ethnicity differences. The aim of the present study was to determine the frequency of EGFR mutations in Turkish patients with NSCLC to highlight the importance of regional differences, and their associations with patient characteristics. Genomic DNA was extracted from formalin-fixed and paraffin-embedded tumor tissue sections of 409 NSCLC patients. The most common EGFR mutations in exons 18, 19, 20 and 21 were detected using BioFilmChip-based microarray assay. The overall EGFR mutation frequency was 16.6%, and the highest mutation frequencies were observed in exon 19 (6.4%) and exon 21 (7.3%). There was a higher frequency of EGFR mutations in females compared with males and in never-smokers compared with smokers (both P
- Published
- 2020
- Full Text
- View/download PDF